More than a decade and over $2.3 billion. That’s the average investment required to bring a new drug to market today, showing just how expensive drug development has become. Research and development (R&D) delays are becoming more common, driving up costs and compounding the risk of failure, especially in areas like pain, neurology, and psychiatry, where trial endpoints are subjective and variability is high.
When trials falter, it is tempting to blame process gaps. Yet many studies fail for a subtler reason: Human behavior distorts the signal we’re trying to measure.
Patients don’t live in a vacuum. They juggle jobs and families, they forget doses, they drop visits, they respond to expectations, and they interpret instructions through very different life experiences. Those factors are not “noise.” They are measurable, and if we plan for them, manageable.
SILENT VARIABLES SABOTAGING SUCCESS
Clinical trials are designed to test biology, but they run in the real world. A participant who is optimistic about a therapy can experience placebo-related improvements that mask drug effects. Someone navigating complex visit schedules may disengage, leading to missing data. Two people on the same dose can diverge, due to mindset, motivation, or how the study was framed.
Historically, sponsors have optimized for biological variation and operational logistics, not psychological heterogeneity. Even when teams recognize adherence, engagement, and placebos as risks, they often address them late (after enrollment slows, after missing data accumulates, after the interim looks noisy). By that point, fixes are expensive or impossible.
MODEL BEHAVIOR EARLY, DON’T CHASE IT LATE
Fortunately, this is starting to change. New approaches in predictive behavioral modeling allow ways to identify, quantify, and plan around patient and human variability from day one. We now have tools that can assess a patient’s likelihood of dropping out, disengaging, or responding to placebo before they ever enter a trial.
Instead of excluding these patients, their behavioral profiles can be used as covariates in the analysis, boosting statistical power without bloating sample size. These adjustments align with recent FDA guidance and allow for more inclusive and human-centric studies. It’s imperative for these models to be embedded in the trial protocols from the start in the statistical analysis plan, in patient consent language, and in site training.
Sponsors can then target support where it will matter most, such as adding check-ins for participants likely to struggle with visit cadence. They can pre-specify behavioral covariates to reduce variance without inflating sample size, and they can equip research centers with practical scripts and timing for expectation-setting and re-engagement.
Crucially, they can protest inclusivity by retaining participants who might otherwise be excluded as “high risk,” while still controlling analytically for the variance those participants introduce. Done well, this shortens timelines, clarifies signals, and improves the fairness and generalizability of findings.
SAFEGUARDS TO COMBAT BEHAVIORAL MODELING LIMITS
These approaches are only as strong as their inputs and implementation. Many behavioral measures are self-reported or context-dependent, so a signal validated in one indication, region, or age group may not transfer cleanly to one another; leaders should expect measurement-invariance checks and external validation across subgroups. Workflow fit matters, too. Coordinators are stretched, and any added questionnaires, dashboards, or alerts must be translated into clear, low-friction actions. Interpretability and governance are essential: black-box scores erode trust, so teams need plain-language rationales for risk flags.
There is also the risk of misuse. Behavioral profiling should not become a proxy for algorithmic exclusion. The aim is to design for inclusion and adjust analytically, not to narrow the sample. Finally, privacy and consent require close attention and rigor. Psychological and engagement data are sensitive so programs must be transparent about how behavioral data will be used in care, analysis, as well as any future research.
WHAT INDUSTRY LEADERS CAN DO NOW
Start early and keep it small. Pick one behavior to improve in this study, whether it be adherence, visit completion, or expectation-setting, and build a simple plan around that. Name how you’ll measure it and how you’ll respond, and include that planning upfront in the trial protocol and analysis. Make it easy to do the right thing.
Use the systems the clinical team already lives in, keep prompts to a minimum, and focus on one or two actions that help people show up and stay engaged. If it does not make participation simpler or the signals clearer, it does not make the cut. Protect participant trust. Be clear about which data you are collecting and why. And collect as little as you need. Compare notes. Share measures and lessons with peers, patient groups, and regulators where you can. Common language and simple standards help everyone move faster.
MINDSHIFT FOR THE FUTURE OF CLINICAL TRIALS
The next generation of clinical trials will be powered not only by biological insight, but by behavioral intelligence. We need to stop treating patient behavior as a liability and start treating it as valued data. Once we do that, we can build smarter trials that reflect the complexity of real life and finally start delivering on the full promise of personalized medicine.